knowledge -WSS

knowledge

author：hotspot 2025-10-03 00:04:08 - browse：5

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Woodcock on FDA’s accelerated approval and her next chapter

WSS

General Catalyst, Summa Health deal will turn on physician buy

The pink breast cancer awareness ribbon needs a redesign

New Ultima Genomics DNA sequencer can read genome for $100

Quicker fix for pulse oximeters urged during FDA public meeting

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Physician subsidies by hospitals soar in wake of No Surprises Act

leisure time

knowledge

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

WHO may add ‘noma' to its list of neglected tropical diseases

Duchenne breakthrough therapy leaves behind pioneering families

Readout Newsletter: XBI biotech index, Akero Therapeutics

Dobbs anniversary: the lost opportunity of abortion as health care

First Opinion Podcast: How to protect health care in times of war

State Dept. review finds Biden bears some blame for Afghanistan failures

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Peter Hotez and the public health issue of online harassment

Telehealth options flood the market as retailers push virtual care

focus

Do digital therapeutics have a future in medicine?

New Ultima Genomics DNA sequencer can read genome for $100

Testing for cancer recurrence creates a new limbo for patients

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Quicker fix for pulse oximeters urged during FDA public meeting

Biden's order seeks to regulate AI risk without stifling innovation

leisure time

focus

leisure time

entertainment